Biocon's subsidiary received FDA approval for a drug in the United States on August 18, 2026.

The entities involved

• Biocon →

  an Indian biopharmaceutical company

  Nothing else this week.

• FDA →
  • NRx Pharmaceuticals is undergoing a first-cycle review of an ANDA for ketamine, noting its strategic importance for the U.S. military and VA.19:54
  • BridgeBio announced on August 14, 2026, that it has submitted New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA).17:22

Related events

• A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Jun 7
• FDA accepts a BLA for biosimilar review and extends its review process to Health Canada.Oct 13
• FDA approval is the goal for product candidates from Daré Bioscience, Inc.Jun 7
• Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.Aug 5
• FDA approval expands patient access to therapies for ACCORD.Jul 10